Chris Tan named Head of new MSD in the Philippines

Manila, Philippines, November 11, 2009 – Following the recent completion of the global merger of parent companies Merck & Co. Inc. and Schering-Plough Corporation, MSD and Schering Plough (Philippines) are now in the process of integrating their respective businesses in the country. Although MSD and Schering-Plough will remain separate legal entities for a period of time, their operations will eventually be integrated under the MSD name, headed by its Managing Director, Chris Tan.

Said Tan: “The Philippines is an integral part of the company’s expanded global presence, and we look forward to continually meeting and exceeding the needs of customers and providing them with the high-quality products and services they have come to expect. MSD is fully committed to bringing innovative medicines and vaccines to Filipinos as well as undertaking educational efforts that benefit patients and doctors and social programs that build the capacity of health professionals and NGOs to improve healthcare in the country.”

Chris started his career at Merck 24 years ago at Merck Frosst Canada, where he quickly rose through various positions in Sales & Marketing and Strategic Planning. In 1995, he joined the Marketing organization at Merck Corporate, New Jersey, USA. His passion to work in Asia drew him to the Asia Pacific division in 1997, where he handled several portfolios as Regional Marketing Director based out of New Jersey. In late 2003, he joined the MSD operations in Thailand and eventually moved to Bangkok on January 1, 2004 to head Sales & Marketing in MSD Thailand Ltd.. He was appointed as Managing Director of MSD Philippines in April 2006.

Chris was born in Malaysia. His first language is English, but he speaks several Asian languages, including Chinese (Fuchien, Mandarin and Cantonese), Bahasa Malaysia, Indonesian and Thai. He is a graduate of the University of Toronto, where he received a B.Sc. degree in Biology/Genetics. He obtained his MBA from Concordia University's John Molson School of Business (Montreal).

The Merck and Schering-Plough merger has created a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long-term shareholder value. The new company is in pole position in a wide range of areas like cardiology, infectious diseases, diabetes, respiratory, vaccines, women's health, sun care and animal health, and now the company is expanding offerings in other areas like neurology, oncology and dermatology and building new strength in categories like biologics.

About Merck
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well. For more information, visit www.merck.com

Forward Looking Statement
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2008 Annual Report on Form 10-K, Schering-Plough’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2009, the proxy statement filed by Merck on June 25, 2009 and each company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

This site is intended for residents of the Philippines. | COPYRIGHT © 2010 MERCK & CO., INC.